MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma
Cancer Science · 2024
DOI: 10.1111/cas.16297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Yoshinori Uchihara und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Osteosarcoma, Temozolomide, DNA Repair Enzymes, Tumor Suppressor Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Children's Cancer Association of Japan.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The prognosis of patients with osteosarcoma who experience recurrence or progression (R/P) is extremely poor, and more effective and less toxic therapies are needed. In the current study, the clinical data of osteosarcoma patients who experienced R/P were retrospectively analyzed to verify the reliability of O‐6‐methylguanine‐DNA methyltransferase (MGMT) protein expression or MGMT promoter methylation for predicting the response to off‐label temozolomide (TMZ)‐containing chemotherapy. Of the 30 evaluable patients, 9 (30%) showed no/low MGMT protein expression, whereas all 16 evaluable patients had unmethylated MGMT promoter irrespective of MGMT protein expression levels. Twenty‐three patients received TMZ‐containing chemotherapy for measurable lesions ( n = 14) or as adjuvant therapy following resection of recurrent lesions ( n = 9). Among 14 patients with radiologically measurable lesions, the objective response rate was higher in the MGMT no/low‐expression group (50.0%) than in the MGMT intermediate/high‐expression group with borderline significance (0%, p = 0.066). The 6‐month progression‐free survival (PFS) rate in patients with radiologically measurable lesions was significantly higher in the MGMT no/low‐expression group (50.0%) than in the MGMT intermediate/high‐expression group (0%, p = 0.036). In the multivariate analysis of the 23 patients receiving TMZ‐containing chemotherapy, MGMT expression and disease status before TMZ‐containing chemotherapy were significantly associated with PFS. No severe adverse effects were observed during TMZ‐containing chemotherapy. MGMT protein expression, but not MGMT promoter methylation, could predict a favorable outcome in patients receiving TMZ‐containing chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
- Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Neurosurgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Pediatrics, Graduate School of Medicine, Kobe University, Kobe, Japan.
ORCID-Profile: Katsutsugu Umeda, Keiji Tasaka, Itaru Kato, Akio Sakamoto, Yoshiki Arakawa, Ayumu Arakawa
Förderung
- Children's Cancer Association of Japan
Zitieren
APA
Uchihara, Y., Umeda, K., Yamada, Y., Ito, H., Tasaka, K., Isobe, K., Akazawa, R., Kawabata, N., Saida, S., Kato, I., Hiramatsu, H., Noguchi, T., Sakamoto, A., Arakawa, Y., Arakawa, A., Yamamoto, N., Hosoya, Y., Uemura, S., Watanabe, K. I., …, & Takita, J. (2024). MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma. Cancer Science. https://doi.org/10.1111/cas.16297
Vancouver
Uchihara Y, Umeda K, Yamada Y, Ito H, Tasaka K, Isobe K, et al. MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma. Cancer Science. 2024. doi:10.1111/cas.16297
BibTeX
@article{Uchihara2024,
author = {Uchihara, Yoshinori and Umeda, Katsutsugu and Yamada, Yosuke and Ito, Hiroaki and Tasaka, Keiji and Isobe, Kiyotaka and Akazawa, Ryo and Kawabata, Naoko and Saida, Satoshi and Kato, Itaru and Hiramatsu, Hidefumi and Noguchi, Takashi and Sakamoto, Akio and Arakawa, Yoshiki and Arakawa, Ayumu and Yamamoto, Nobuyuki and Hosoya, Yosuke and Uemura, Suguru and Watanabe, Ken-Ichiro and Sano, Hideki and Taga, Takashi and Takita, Junko},
title = {MGMT protein expression is a reliable predictive biomarker for temozolomide‐containing chemotherapy in osteosarcoma},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16297}
}
EUVIMED